INDOCO REMEDIES LTD.

Indoco Remedies Limited reported its Q1 FY27 earnings during an earnings conference call held on July 28, 2026. Management highlighted a 5.8% year-on-year growth in standalone operational revenue to INR4,081 million, with consolidated revenue increasing by 8.2% to INR4,662 million. Standalone EBITDA rose to INR422 million, reflecting a margin of 10.3%. The company achieved significant regulatory milestones, including successful audits and certifications for its manufacturing facilities. The domestic formulations business generated INR2,040 million in revenue, while international formulations contributed 35% of total revenue. Management noted challenges in the international market, particularly in Europe and emerging markets, but expressed confidence in sustaining profitable growth. They emphasized a focus on scaling high-margin brands and optimizing operational efficiency. The call concluded with management addressing questions regarding debt levels, margins, and future growth prospects.

Management reported growth in revenues and operational efficiency while acknowledging challenges in certain markets.